|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits with other institutions | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Securities available for sale, at fair value, amortized cost of $120,152 and $126,197, respectively | ||||||||||||||||||||
| Restricted investments, at cost | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Net Loans | ||||||||||||||||||||
| Bank premises and equipment, net | ||||||||||||||||||||
| Other real estate owned, net of allowance | ||||||||||||||||||||
| Bank owned life insurance | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Shareholders’ Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Noninterest bearing demand deposits | ||||||||||||||||||||
| Savings and interest bearing demand deposits | ||||||||||||||||||||
| Time deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Federal funds purchased | ||||||||||||||||||||
| Federal Home Loan Bank advances, short-term | ||||||||||||||||||||
| Federal Home Loan Bank advances, long-term | ||||||||||||||||||||
| Subordinated debt, net of unamortized issuance costs | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ Equity | ||||||||||||||||||||
| Preferred stock, $10 par value; 500,000 shares authorized and unissued | ||||||||||||||||||||
| Common stock, $2.50 par value; authorized 10,000,000 shares; issued and outstanding 2026, 5,411,615 including 86,912 shares of unvested restricted stock; issued and outstanding 2025, 5,374,205 including 68,476 shares of unvested restricted stock | ||||||||||||||||||||
| Surplus | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
